| NCT03055312 | III | AR inhibitor | Bicalutamide vs. TPC (taxotere and xeloda, GT or gemcitabine and carboplatin) | Recruiting | 18–70 years, female (262) | December 2016–December 2020 | Zhong-yu Yuan, Sun Yat-sen University | China | Hwang et al. (2019) |
Bicalutamide | NCT00468715 | II | AR inhibitor | Bicalutamide | Active, not recruiting | 18–120 years, all (28) | May 2007–March 2021 | Memorial Sloan-Kettering Cancer Center | United States | Gucalp et al. (2013) |
| NCT02353988 | II | AR inhibitor | Bicalutamide vs. physician’s choice | Not yet recruiting | 18–70 years, female (60) | January 2015–January 2017 | Xiaoxiang Guan, Jinling Hospital, China | Not Provided | Gucalp et al. (2013) |
| NCT01889238 | II | AR inhibitor | Enza | Active, not recruiting | 18+ years, female (118) | June 2013–April 2020 | Pfizer | Canada, Italy, Spain, United Kingdom, United States | Traina et al. (2015) |
Enza | NCT02750358 | II | AR inhibitor | Enza | Active, not recruiting | 18+ years, female (200) | April 2016–May 2021 | Memorial Sloan-Kettering Cancer Cente | United States | Lyons et al. (2018) |
| NCT02689427 | IIB | AR inhibitor + antimicrotubule | Enza + paclitaxel | Recruiting | 18+ years, all (37) | February 2016–September 2020 | M.D. Anderson Cancer Center | United States | Gerratana et al. (2018) |
Abiraterone acetate | NCT00755885 | II | CYP17 inhibitor | Abiraterone acetate | Completed | 18+, female (77) | September 2008–June 2016 | Cancer Research UK | United Kingdom | Gerratana et al. (2018) |
| NCT01842321 | II | CYP17 inhibitor | Abiraterone acetate + prednisone | Active, not recruiting | 18+ years, female (31) | April 2013–July 2015 | UNICANCER | France | Bonnefoi et al. (2016) |
Seviteronel | NCT02580448 | II | CYP17 inhibitor | Seviteronel | Completed | 18+ years, all (175) | October 2015–January 2019 | Innocrin Pharmaceutical | United States | Bardia et al. (2018); Michmerhuizen et al. (2020) |
| NCT02130700 | II | CYP17 inhibitor | Seviteronel | Completed | 18+ years, all (175) | April 2014–September 2017 | Innocrin Pharmaceutical | United States | Michmerhuizen et al. (2020) |
CDK4/6 + AR inhibition | NCT03090165 | I/II | AR inhibitor + CDK 4/6 inhibitor | Bicalutamide + ribociclib | Active, not recruiting | 18+ years, all (11) | March 2017–September 2022 | Ruth O’Regan, M.D., Big Ten Cancer Research Consortium | United States | Wang et al. (2021) |
| NCT02605486 | I/II | AR inhibitor + CDK 4/6 inhibitor | Bicalutamide + palbociclib | Active, not recruiting | 18+ years, female (46) | November 2015–November 2022 | Memorial Sloan-Kettering Cancer Center | United States United States | Gucalp et al. (2016); Wang et al. (2021) |
| NCT02457910 | Ib/II | AR inhibitor + PI3K inhibitor | Enza + taselisib | Active, not recruiting | 18+ years, all (30) | May 2015–May 7, 2020 | Vandana Abramson, Vanderbilt-Ingram Cancer Center | United States | Lehmann et al. (2020) |
AR inhibitor + PI3K inhibitor | NCT01884285 | I | AR inhibitor + PI3K inhibitor+ mTOR inhibitor | AZD8186 + AZD2014+ abiraterone | Completed | 18+ years, all (147) | June 2013–March 2019 | AstraZeneca | Canada, Spain, United Kingdom, United States | Lebert et al. (2018) |
| NCT03207529 | I | AR inhibitor + PI3K inhibitor | Enza + alpelisib | Recruiting | 18+ years, all (28) | June 2017–December 2020 | M.D. Anderson Cancer Center | United States | Garrido-Castro et al. (2019) |